Decongestant use in first trimester may raise risk of birth defects

07/22/2013 | Reuters

Babies born to women who took the decongestant phenylephrine during their first trimester of pregnancy were eight times more likely to have endocardial cushion defect than unexposed peers, while first-trimester use of phenylpropanolamine was associated with an eightfold increased risk of ear and stomach defects. Researchers also found first-trimester use of pseudoephedrine was tied to a threefold higher risk of so-called limb reduction defects. The findings were published in the American Journal of Epidemiology.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park